Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 37 | 2024 | 272 | 11.930 |
Why?
|
Lung Neoplasms | 19 | 2023 | 2262 | 3.090 |
Why?
|
Breast Neoplasms | 25 | 2023 | 2903 | 3.060 |
Why?
|
Neoplasms | 29 | 2023 | 2898 | 2.680 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2023 | 1075 | 2.200 |
Why?
|
Neoplasm Metastasis | 22 | 2023 | 1056 | 2.100 |
Why?
|
Radiotherapy | 13 | 2020 | 328 | 1.910 |
Why?
|
Antibodies, Monoclonal, Humanized | 8 | 2023 | 930 | 1.790 |
Why?
|
Radiation Oncology | 12 | 2023 | 119 | 1.740 |
Why?
|
Chemoradiotherapy | 4 | 2021 | 301 | 1.390 |
Why?
|
Radiotherapy, Intensity-Modulated | 12 | 2021 | 173 | 1.280 |
Why?
|
Anus Neoplasms | 4 | 2009 | 30 | 1.230 |
Why?
|
Brain Neoplasms | 10 | 2023 | 763 | 1.190 |
Why?
|
Clinical Clerkship | 7 | 2018 | 116 | 1.170 |
Why?
|
Combined Modality Therapy | 25 | 2023 | 1686 | 1.170 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 18 | 2021 | 176 | 1.160 |
Why?
|
Humans | 114 | 2024 | 86643 | 1.000 |
Why?
|
Biomarkers, Tumor | 3 | 2021 | 1464 | 0.860 |
Why?
|
Antineoplastic Agents, Immunological | 3 | 2020 | 185 | 0.840 |
Why?
|
Radiotherapy Dosage | 17 | 2021 | 468 | 0.790 |
Why?
|
Radiotherapy, Conformal | 6 | 2020 | 83 | 0.780 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2021 | 2438 | 0.780 |
Why?
|
Disease-Free Survival | 9 | 2022 | 1204 | 0.730 |
Why?
|
Transforming Growth Factor beta | 2 | 2023 | 301 | 0.730 |
Why?
|
Curriculum | 6 | 2018 | 539 | 0.710 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2012 | 1076 | 0.710 |
Why?
|
Female | 49 | 2023 | 44532 | 0.690 |
Why?
|
Immunotherapy | 9 | 2023 | 629 | 0.680 |
Why?
|
Radiobiology | 1 | 2018 | 13 | 0.650 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2018 | 54 | 0.640 |
Why?
|
Antibodies, Monoclonal | 3 | 2021 | 1376 | 0.620 |
Why?
|
Prognosis | 13 | 2022 | 3679 | 0.620 |
Why?
|
Genetic Therapy | 4 | 2007 | 342 | 0.620 |
Why?
|
Aged, 80 and over | 20 | 2021 | 6509 | 0.590 |
Why?
|
T-Lymphocytes | 3 | 2021 | 1195 | 0.580 |
Why?
|
Mastectomy | 3 | 2017 | 243 | 0.580 |
Why?
|
Glioblastoma | 5 | 2020 | 255 | 0.570 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2017 | 865 | 0.560 |
Why?
|
Middle Aged | 33 | 2023 | 25028 | 0.560 |
Why?
|
Phenanthridines | 5 | 2000 | 24 | 0.560 |
Why?
|
Aged | 32 | 2021 | 18415 | 0.550 |
Why?
|
Apoptosis | 8 | 2021 | 1683 | 0.540 |
Why?
|
Career Choice | 2 | 2014 | 139 | 0.530 |
Why?
|
Viruses | 3 | 2007 | 78 | 0.530 |
Why?
|
Ceramides | 4 | 2000 | 35 | 0.520 |
Why?
|
Antineoplastic Agents | 8 | 2021 | 2360 | 0.510 |
Why?
|
Cranial Irradiation | 1 | 2014 | 36 | 0.500 |
Why?
|
Protein Kinase C | 5 | 2000 | 270 | 0.480 |
Why?
|
Radiation Injuries | 6 | 2020 | 155 | 0.470 |
Why?
|
Treatment Outcome | 17 | 2023 | 7993 | 0.460 |
Why?
|
Adult | 31 | 2021 | 25648 | 0.440 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2014 | 113 | 0.430 |
Why?
|
Radiodermatitis | 1 | 2011 | 10 | 0.420 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 100 | 0.410 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2001 | 94 | 0.400 |
Why?
|
Prostatic Neoplasms | 4 | 2021 | 1721 | 0.400 |
Why?
|
Head and Neck Neoplasms | 6 | 2009 | 1052 | 0.390 |
Why?
|
Students, Medical | 5 | 2016 | 384 | 0.380 |
Why?
|
Male | 31 | 2023 | 40965 | 0.370 |
Why?
|
Survival Rate | 7 | 2021 | 1863 | 0.370 |
Why?
|
Breast | 1 | 2011 | 288 | 0.360 |
Why?
|
Statistics as Topic | 1 | 2010 | 238 | 0.350 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2019 | 172 | 0.350 |
Why?
|
MicroRNAs | 4 | 2016 | 534 | 0.350 |
Why?
|
Prospective Studies | 8 | 2022 | 4213 | 0.350 |
Why?
|
Gastrointestinal Tract | 2 | 2021 | 191 | 0.350 |
Why?
|
Magnetic Resonance Imaging | 3 | 2018 | 3362 | 0.350 |
Why?
|
Program Evaluation | 6 | 2018 | 297 | 0.340 |
Why?
|
Pneumonia | 2 | 2022 | 179 | 0.330 |
Why?
|
Obesity | 2 | 2014 | 963 | 0.330 |
Why?
|
Ipilimumab | 2 | 2021 | 58 | 0.330 |
Why?
|
Comorbidity | 2 | 2020 | 943 | 0.320 |
Why?
|
Liver Neoplasms | 3 | 2024 | 736 | 0.320 |
Why?
|
Fluorouracil | 7 | 2009 | 556 | 0.320 |
Why?
|
Mitomycin | 4 | 2009 | 29 | 0.320 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 157 | 0.300 |
Why?
|
Cell Survival | 4 | 2019 | 969 | 0.300 |
Why?
|
Radiation, Ionizing | 4 | 2021 | 121 | 0.290 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 292 | 0.290 |
Why?
|
Enzyme Inhibitors | 6 | 2018 | 639 | 0.290 |
Why?
|
Pituitary Neoplasms | 1 | 2006 | 62 | 0.280 |
Why?
|
Patient Selection | 3 | 2022 | 685 | 0.280 |
Why?
|
Neoplasm Proteins | 2 | 2021 | 532 | 0.280 |
Why?
|
Sphingomyelin Phosphodiesterase | 4 | 2000 | 21 | 0.270 |
Why?
|
Bone Marrow | 1 | 2007 | 435 | 0.270 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 859 | 0.270 |
Why?
|
Clinical Competence | 3 | 2018 | 751 | 0.270 |
Why?
|
Gene Expression Profiling | 4 | 2020 | 1384 | 0.270 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2021 | 592 | 0.260 |
Why?
|
Bevacizumab | 5 | 2021 | 281 | 0.260 |
Why?
|
Naphthalenes | 4 | 1999 | 45 | 0.260 |
Why?
|
Dacarbazine | 2 | 2015 | 102 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2021 | 1313 | 0.250 |
Why?
|
Follow-Up Studies | 7 | 2021 | 3640 | 0.240 |
Why?
|
Program Development | 2 | 2015 | 124 | 0.240 |
Why?
|
Melanoma | 2 | 2023 | 459 | 0.240 |
Why?
|
Radiotherapy, Image-Guided | 2 | 2016 | 56 | 0.240 |
Why?
|
Radioimmunotherapy | 1 | 2023 | 25 | 0.240 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2024 | 69 | 0.230 |
Why?
|
Adenocarcinoma | 5 | 2012 | 1169 | 0.220 |
Why?
|
Radiometry | 3 | 2014 | 53 | 0.220 |
Why?
|
Tomography, X-Ray Computed | 6 | 2020 | 2601 | 0.220 |
Why?
|
Radiation Pneumonitis | 1 | 2022 | 21 | 0.220 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2018 | 188 | 0.210 |
Why?
|
Animals | 19 | 2023 | 26582 | 0.210 |
Why?
|
Skin | 2 | 2016 | 554 | 0.210 |
Why?
|
Neoplasms, Second Primary | 3 | 2015 | 252 | 0.210 |
Why?
|
Anetoderma | 1 | 2021 | 2 | 0.210 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 7 | 0.210 |
Why?
|
Re-Irradiation | 1 | 2021 | 15 | 0.210 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 311 | 0.200 |
Why?
|
Loss of Function Mutation | 1 | 2021 | 42 | 0.200 |
Why?
|
Mastectomy, Segmental | 3 | 2011 | 93 | 0.200 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 418 | 0.200 |
Why?
|
Exanthema | 1 | 2021 | 36 | 0.200 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 104 | 0.200 |
Why?
|
Erythroid Precursor Cells | 1 | 2021 | 32 | 0.200 |
Why?
|
Benzophenanthridines | 5 | 2000 | 23 | 0.190 |
Why?
|
Butyrates | 1 | 2021 | 42 | 0.190 |
Why?
|
Alkaloids | 5 | 2000 | 45 | 0.190 |
Why?
|
Gliosarcoma | 1 | 2020 | 7 | 0.190 |
Why?
|
Mice | 12 | 2023 | 11352 | 0.190 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2020 | 73 | 0.190 |
Why?
|
Cytochrome c Group | 1 | 2000 | 82 | 0.180 |
Why?
|
Memantine | 1 | 2020 | 10 | 0.180 |
Why?
|
Interferon Type I | 1 | 2021 | 175 | 0.180 |
Why?
|
Patient Care Management | 1 | 2020 | 31 | 0.180 |
Why?
|
Critical Pathways | 1 | 2020 | 35 | 0.180 |
Why?
|
Motivation | 1 | 2022 | 287 | 0.180 |
Why?
|
Retrospective Studies | 8 | 2023 | 8489 | 0.180 |
Why?
|
Risk Factors | 4 | 2018 | 5417 | 0.180 |
Why?
|
NF-kappa B | 1 | 2023 | 444 | 0.180 |
Why?
|
Sphingomyelins | 2 | 1996 | 16 | 0.180 |
Why?
|
Neoplasm Staging | 6 | 2021 | 1939 | 0.180 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2016 | 70 | 0.180 |
Why?
|
Time Factors | 6 | 2020 | 5210 | 0.180 |
Why?
|
Tumor Burden | 4 | 2017 | 289 | 0.180 |
Why?
|
Down-Regulation | 2 | 2017 | 504 | 0.180 |
Why?
|
Body Mass Index | 2 | 2014 | 770 | 0.180 |
Why?
|
Internship and Residency | 3 | 2018 | 1004 | 0.170 |
Why?
|
Motion | 2 | 2017 | 85 | 0.170 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2018 | 159 | 0.170 |
Why?
|
Glioma | 1 | 2021 | 285 | 0.170 |
Why?
|
Sphingosine | 2 | 1997 | 71 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 860 | 0.170 |
Why?
|
Cells, Cultured | 4 | 2017 | 2818 | 0.170 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2019 | 176 | 0.170 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2020 | 64 | 0.170 |
Why?
|
Organs at Risk | 4 | 2021 | 41 | 0.170 |
Why?
|
B7-H1 Antigen | 2 | 2018 | 250 | 0.170 |
Why?
|
United States | 11 | 2018 | 6672 | 0.160 |
Why?
|
Palliative Medicine | 1 | 2018 | 11 | 0.160 |
Why?
|
Mediastinum | 1 | 2018 | 46 | 0.160 |
Why?
|
PTEN Phosphohydrolase | 1 | 2019 | 128 | 0.160 |
Why?
|
Breath Holding | 1 | 2018 | 22 | 0.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 123 | 0.160 |
Why?
|
Regression Analysis | 2 | 2011 | 596 | 0.160 |
Why?
|
Educational Measurement | 2 | 2018 | 225 | 0.160 |
Why?
|
Astrocytoma | 1 | 2018 | 82 | 0.160 |
Why?
|
Feasibility Studies | 3 | 2021 | 751 | 0.160 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 101 | 0.160 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 269 | 0.160 |
Why?
|
Radiation Oncologists | 1 | 2017 | 13 | 0.160 |
Why?
|
Societies, Scientific | 1 | 2017 | 44 | 0.150 |
Why?
|
Education, Medical, Graduate | 2 | 2018 | 369 | 0.150 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 138 | 0.150 |
Why?
|
Craniocerebral Trauma | 1 | 1997 | 52 | 0.150 |
Why?
|
Transcription Factors | 2 | 2023 | 1565 | 0.150 |
Why?
|
Credentialing | 1 | 2016 | 13 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2014 | 468 | 0.150 |
Why?
|
Isoenzymes | 1 | 1997 | 271 | 0.150 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 329 | 0.140 |
Why?
|
Lymph Nodes | 2 | 2014 | 533 | 0.140 |
Why?
|
Selection Bias | 1 | 2016 | 37 | 0.140 |
Why?
|
Hippocampus | 1 | 2020 | 442 | 0.140 |
Why?
|
Benchmarking | 1 | 2016 | 78 | 0.140 |
Why?
|
Terminology as Topic | 1 | 2017 | 217 | 0.140 |
Why?
|
Mammography | 2 | 2010 | 463 | 0.140 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2016 | 80 | 0.140 |
Why?
|
Standard of Care | 1 | 2016 | 79 | 0.130 |
Why?
|
Biopsy | 2 | 2018 | 1163 | 0.130 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 72 | 0.130 |
Why?
|
Cognition | 1 | 2020 | 570 | 0.130 |
Why?
|
Teaching | 1 | 2016 | 147 | 0.130 |
Why?
|
Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.130 |
Why?
|
Disease Management | 1 | 2017 | 327 | 0.130 |
Why?
|
Tumor Cells, Cultured | 5 | 2000 | 1041 | 0.130 |
Why?
|
Lymphocytes | 1 | 1997 | 464 | 0.130 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2015 | 138 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
Needs Assessment | 2 | 2014 | 154 | 0.130 |
Why?
|
Gastrointestinal Microbiome | 1 | 2021 | 455 | 0.130 |
Why?
|
Guidelines as Topic | 1 | 2015 | 162 | 0.120 |
Why?
|
Benzimidazoles | 1 | 2015 | 140 | 0.120 |
Why?
|
Medical Oncology | 1 | 2018 | 359 | 0.120 |
Why?
|
Robotics | 1 | 2017 | 267 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 238 | 0.120 |
Why?
|
Boston | 1 | 2014 | 33 | 0.120 |
Why?
|
Patient Positioning | 1 | 2014 | 63 | 0.120 |
Why?
|
Gene Transfer Techniques | 3 | 2001 | 152 | 0.120 |
Why?
|
Pediatrics | 1 | 2018 | 344 | 0.120 |
Why?
|
Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
Consumer Behavior | 1 | 2014 | 29 | 0.120 |
Why?
|
Metal Nanoparticles | 2 | 2010 | 30 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 508 | 0.120 |
Why?
|
Hodgkin Disease | 1 | 2015 | 177 | 0.120 |
Why?
|
Gold | 2 | 2010 | 41 | 0.120 |
Why?
|
Bone Neoplasms | 1 | 2016 | 322 | 0.120 |
Why?
|
Hospitals, Teaching | 1 | 2014 | 115 | 0.110 |
Why?
|
Young Adult | 8 | 2018 | 5976 | 0.110 |
Why?
|
Central Nervous System | 1 | 2014 | 151 | 0.110 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2013 | 213 | 0.110 |
Why?
|
Data Interpretation, Statistical | 1 | 2014 | 297 | 0.110 |
Why?
|
Child | 4 | 2018 | 6927 | 0.110 |
Why?
|
Cohort Studies | 3 | 2023 | 2767 | 0.110 |
Why?
|
Carcinoma | 1 | 2016 | 436 | 0.110 |
Why?
|
Cell Line, Tumor | 6 | 2019 | 2426 | 0.110 |
Why?
|
Lung | 3 | 2014 | 1170 | 0.110 |
Why?
|
Enzyme Activation | 3 | 2000 | 692 | 0.110 |
Why?
|
Neurosurgical Procedures | 1 | 2014 | 213 | 0.110 |
Why?
|
Eye Neoplasms | 1 | 2012 | 27 | 0.110 |
Why?
|
Child, Preschool | 2 | 2016 | 3612 | 0.110 |
Why?
|
Analysis of Variance | 2 | 2012 | 912 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 320 | 0.100 |
Why?
|
Carcinoma, Large Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 138 | 0.100 |
Why?
|
Myeloid Cells | 2 | 2023 | 98 | 0.100 |
Why?
|
Relative Biological Effectiveness | 2 | 2008 | 13 | 0.100 |
Why?
|
Spinal Cord Neoplasms | 1 | 2012 | 48 | 0.100 |
Why?
|
Clinical Trials as Topic | 3 | 2017 | 1169 | 0.100 |
Why?
|
Risk Assessment | 2 | 2020 | 2261 | 0.100 |
Why?
|
RNA-Binding Proteins | 2 | 2023 | 246 | 0.100 |
Why?
|
Organ Size | 1 | 2011 | 364 | 0.100 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 329 | 0.100 |
Why?
|
Deoxyglucose | 1 | 2010 | 37 | 0.100 |
Why?
|
Pyrans | 1 | 2010 | 10 | 0.100 |
Why?
|
Reproducibility of Results | 5 | 2018 | 2705 | 0.090 |
Why?
|
Acetamides | 1 | 2010 | 26 | 0.090 |
Why?
|
Mortality | 1 | 2011 | 149 | 0.090 |
Why?
|
Mice, Nude | 3 | 2010 | 790 | 0.090 |
Why?
|
Prodrugs | 2 | 2001 | 46 | 0.090 |
Why?
|
Signal Transduction | 2 | 2023 | 3241 | 0.090 |
Why?
|
Surveys and Questionnaires | 4 | 2018 | 2501 | 0.090 |
Why?
|
X-Ray Microtomography | 1 | 2010 | 80 | 0.090 |
Why?
|
Tumor Stem Cell Assay | 1 | 2009 | 35 | 0.090 |
Why?
|
Genes, p53 | 2 | 2001 | 109 | 0.090 |
Why?
|
Adaptive Immunity | 2 | 2021 | 164 | 0.090 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2024 | 155 | 0.090 |
Why?
|
Infant | 1 | 2016 | 3046 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2010 | 150 | 0.090 |
Why?
|
Tamoxifen | 1 | 2010 | 168 | 0.090 |
Why?
|
Chicago | 1 | 2014 | 1379 | 0.090 |
Why?
|
Ethanolamines | 2 | 2000 | 32 | 0.080 |
Why?
|
Oleic Acids | 2 | 2000 | 26 | 0.080 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.080 |
Why?
|
Genetic Vectors | 2 | 2001 | 439 | 0.080 |
Why?
|
Endocannabinoids | 2 | 2000 | 27 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 2 | 1999 | 114 | 0.080 |
Why?
|
Contrast Media | 2 | 2010 | 1078 | 0.080 |
Why?
|
Cell Proliferation | 2 | 2013 | 1578 | 0.080 |
Why?
|
Cisplatin | 2 | 2007 | 612 | 0.080 |
Why?
|
Radiation Dosage | 2 | 2023 | 227 | 0.080 |
Why?
|
Respiratory Mechanics | 1 | 2008 | 102 | 0.080 |
Why?
|
Leukopenia | 1 | 2007 | 65 | 0.080 |
Why?
|
Transplantation, Heterologous | 2 | 2000 | 363 | 0.080 |
Why?
|
Recurrence | 1 | 2010 | 1139 | 0.080 |
Why?
|
Pelvis | 1 | 2007 | 95 | 0.080 |
Why?
|
Neutropenia | 1 | 2007 | 215 | 0.070 |
Why?
|
Cell Division | 2 | 2000 | 696 | 0.070 |
Why?
|
Actins | 1 | 2010 | 451 | 0.070 |
Why?
|
Drug Synergism | 2 | 1999 | 303 | 0.070 |
Why?
|
Models, Statistical | 1 | 2010 | 574 | 0.070 |
Why?
|
Anemia | 1 | 2007 | 128 | 0.070 |
Why?
|
Phantoms, Imaging | 1 | 2009 | 429 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2007 | 183 | 0.070 |
Why?
|
Stereotaxic Techniques | 1 | 2006 | 69 | 0.070 |
Why?
|
Disease Progression | 3 | 2018 | 1531 | 0.070 |
Why?
|
Lymphatic Metastasis | 3 | 2016 | 486 | 0.070 |
Why?
|
Age Factors | 1 | 2010 | 1851 | 0.070 |
Why?
|
Algorithms | 4 | 2018 | 1830 | 0.070 |
Why?
|
ErbB Receptors | 2 | 2023 | 485 | 0.070 |
Why?
|
Interferon-gamma | 2 | 2019 | 444 | 0.060 |
Why?
|
Postoperative Care | 2 | 2017 | 221 | 0.060 |
Why?
|
Thoracic Wall | 2 | 2014 | 21 | 0.060 |
Why?
|
Histones | 1 | 2006 | 311 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 1673 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2004 | 233 | 0.060 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 3092 | 0.060 |
Why?
|
Software | 2 | 2017 | 654 | 0.060 |
Why?
|
Bile Duct Neoplasms | 1 | 2004 | 79 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2006 | 266 | 0.060 |
Why?
|
Heart | 2 | 2018 | 539 | 0.060 |
Why?
|
Lymph Node Excision | 1 | 2005 | 217 | 0.060 |
Why?
|
Palliative Care | 1 | 2004 | 257 | 0.050 |
Why?
|
Quality of Life | 2 | 2021 | 1585 | 0.050 |
Why?
|
Technology, Radiologic | 2 | 2016 | 103 | 0.050 |
Why?
|
Models, Biological | 1 | 2008 | 1749 | 0.050 |
Why?
|
Fatigue | 1 | 2021 | 174 | 0.050 |
Why?
|
Vancomycin | 1 | 2021 | 72 | 0.050 |
Why?
|
Microscopy, Electron, Transmission | 2 | 2010 | 134 | 0.050 |
Why?
|
Prone Position | 1 | 2020 | 56 | 0.050 |
Why?
|
Antiparkinson Agents | 1 | 2020 | 15 | 0.050 |
Why?
|
Risk Management | 1 | 2020 | 43 | 0.050 |
Why?
|
Permeability | 1 | 2000 | 137 | 0.050 |
Why?
|
Placebos | 1 | 2020 | 218 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2011 | 458 | 0.040 |
Why?
|
Administration, Oral | 1 | 2021 | 684 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 130 | 0.040 |
Why?
|
Cytokines | 1 | 2023 | 776 | 0.040 |
Why?
|
Infection Control | 1 | 2020 | 115 | 0.040 |
Why?
|
Photochemotherapy | 1 | 1999 | 97 | 0.040 |
Why?
|
Self-Assessment | 1 | 2018 | 47 | 0.040 |
Why?
|
Radiation Tolerance | 1 | 2019 | 168 | 0.040 |
Why?
|
Pancreatic Neoplasms | 1 | 2004 | 645 | 0.040 |
Why?
|
Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
Interdisciplinary Studies | 1 | 2018 | 20 | 0.040 |
Why?
|
Body Weight | 1 | 2000 | 459 | 0.040 |
Why?
|
Spirometry | 1 | 2018 | 66 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 1 | 2020 | 557 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 364 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2020 | 236 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 503 | 0.040 |
Why?
|
Survival Analysis | 2 | 2015 | 1538 | 0.040 |
Why?
|
Ceramidases | 1 | 1997 | 4 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2021 | 409 | 0.040 |
Why?
|
Advisory Committees | 1 | 2017 | 90 | 0.040 |
Why?
|
Amidohydrolases | 1 | 1997 | 18 | 0.040 |
Why?
|
Virus Replication | 1 | 1999 | 319 | 0.040 |
Why?
|
Endopeptidases | 1 | 1997 | 116 | 0.040 |
Why?
|
Bacteria | 1 | 2021 | 447 | 0.040 |
Why?
|
Reference Standards | 1 | 2017 | 159 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 1991 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2023 | 1196 | 0.040 |
Why?
|
Linear Models | 2 | 2009 | 421 | 0.040 |
Why?
|
Head | 1 | 2017 | 132 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2023 | 1920 | 0.040 |
Why?
|
Proton Therapy | 1 | 2016 | 27 | 0.040 |
Why?
|
Respiration | 1 | 2018 | 262 | 0.040 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 71 | 0.040 |
Why?
|
Mitochondria | 1 | 2000 | 535 | 0.040 |
Why?
|
Hydrolysis | 1 | 1996 | 141 | 0.040 |
Why?
|
Research Personnel | 1 | 2016 | 67 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 153 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1998 | 381 | 0.030 |
Why?
|
Stomach | 1 | 2016 | 108 | 0.030 |
Why?
|
Deception | 1 | 2015 | 20 | 0.030 |
Why?
|
Artifacts | 1 | 2017 | 244 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 2 | 2014 | 579 | 0.030 |
Why?
|
Cell Movement | 1 | 2019 | 758 | 0.030 |
Why?
|
Competitive Behavior | 1 | 2015 | 28 | 0.030 |
Why?
|
School Admission Criteria | 1 | 2015 | 23 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2013 | 2232 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2019 | 1540 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2020 | 1823 | 0.030 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1999 | 383 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2017 | 357 | 0.030 |
Why?
|
Spinal Cord | 1 | 2016 | 249 | 0.030 |
Why?
|
Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 59 | 0.030 |
Why?
|
Lymphoma, B-Cell | 1 | 1996 | 103 | 0.030 |
Why?
|
Cell Nucleus | 1 | 1997 | 579 | 0.030 |
Why?
|
Genes, APC | 1 | 1994 | 26 | 0.030 |
Why?
|
Rotation | 1 | 2014 | 89 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2019 | 1924 | 0.030 |
Why?
|
Liposomes | 1 | 1994 | 91 | 0.030 |
Why?
|
Biomarkers | 2 | 2014 | 1718 | 0.030 |
Why?
|
Surgical Instruments | 1 | 2014 | 57 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 1999 | 1135 | 0.030 |
Why?
|
Paclitaxel | 2 | 2006 | 460 | 0.030 |
Why?
|
Necrosis | 1 | 2014 | 204 | 0.030 |
Why?
|
Self Concept | 1 | 2014 | 133 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 894 | 0.030 |
Why?
|
Equipment Design | 1 | 2014 | 406 | 0.030 |
Why?
|
Data Collection | 1 | 2014 | 372 | 0.030 |
Why?
|
Adolescent | 2 | 2015 | 8981 | 0.030 |
Why?
|
Cervical Vertebrae | 1 | 2012 | 79 | 0.030 |
Why?
|
Internet | 1 | 2014 | 312 | 0.030 |
Why?
|
Colon | 1 | 1994 | 496 | 0.020 |
Why?
|
SEER Program | 1 | 2011 | 190 | 0.020 |
Why?
|
Decision Making | 1 | 2016 | 642 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2011 | 270 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2011 | 369 | 0.020 |
Why?
|
Neural Stem Cells | 1 | 2011 | 58 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2011 | 260 | 0.020 |
Why?
|
Spiro Compounds | 1 | 2010 | 25 | 0.020 |
Why?
|
Gene Expression | 1 | 1994 | 1284 | 0.020 |
Why?
|
Drug Design | 1 | 2010 | 124 | 0.020 |
Why?
|
Biological Transport | 1 | 2010 | 396 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2013 | 559 | 0.020 |
Why?
|
Body Burden | 1 | 2008 | 9 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 1036 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 1197 | 0.020 |
Why?
|
Leucovorin | 1 | 2006 | 218 | 0.020 |
Why?
|
Organ Specificity | 1 | 2006 | 258 | 0.020 |
Why?
|
Mandibular Diseases | 1 | 2005 | 16 | 0.020 |
Why?
|
Osteoradionecrosis | 1 | 2005 | 18 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.020 |
Why?
|
Mastectomy, Radical | 1 | 2005 | 10 | 0.020 |
Why?
|
Hydroxyurea | 1 | 2005 | 239 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 265 | 0.020 |
Why?
|
Carboplatin | 1 | 2006 | 286 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2009 | 556 | 0.020 |
Why?
|
Treatment Failure | 1 | 2005 | 285 | 0.020 |
Why?
|
Camptothecin | 1 | 2005 | 189 | 0.020 |
Why?
|
Neuroectodermal Tumors | 1 | 2004 | 2 | 0.020 |
Why?
|
Axilla | 1 | 2005 | 99 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2005 | 237 | 0.020 |
Why?
|
DNA Damage | 1 | 2006 | 366 | 0.020 |
Why?
|
Computer Simulation | 1 | 2008 | 1078 | 0.010 |
Why?
|
Preoperative Care | 1 | 2006 | 397 | 0.010 |
Why?
|
Survival | 1 | 2003 | 21 | 0.010 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2004 | 236 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 999 | 0.010 |
Why?
|
Rats | 2 | 1998 | 3990 | 0.010 |
Why?
|
Biotransformation | 1 | 1998 | 50 | 0.010 |
Why?
|
Cell Death | 1 | 1999 | 256 | 0.010 |
Why?
|
Light | 1 | 1998 | 289 | 0.010 |
Why?
|
Adenoviridae | 1 | 1997 | 345 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1999 | 1961 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 1994 | 71 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 1994 | 1219 | 0.010 |
Why?
|
Base Sequence | 1 | 1994 | 2330 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1994 | 3030 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 1994 | 797 | 0.010 |
Why?
|